Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Co-trimoxazole + doxycycline is a combination of two antibiotics used together primarily for the treatment of certain bacterial infections where dual therapy is indicated. Co-trimoxazole (also known as trimethoprim-sulfamethoxazole or TMP-SMX) combines two agents that inhibit successive steps in the bacterial folate synthesis pathway—sulfamethoxazole inhibits dihydropteroate synthase and trimethoprim inhibits dihydrofolate reductase—resulting in synergistic bactericidal activity[2][3][4]. Doxycycline is a tetracycline-class antibiotic that inhibits protein synthesis by binding to the 30S ribosomal subunit of bacteria[9]. The combination has been studied and used particularly for diseases such as brucellosis and melioidosis, especially during eradication phases or when other regimens are contraindicated or less effective[5][8]. This regimen may be chosen based on local guidelines, resistance patterns, or patient-specific factors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on co-trimoxazole + doxycycline.